You are here

Topic 374: Topical Delivery of Nanoformulated Bioactive Chemopreventive Agent in Skin Cancer

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N91018C00019-0-0-0
Agency Tracking Number: N43CA180019
Amount: $288,945.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
5 University Place, RENSSELAER, NY, 12144
DUNS: 196257591
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 Shaker Mousa
 (518) 496-2880
 shaker.mousa@gmail.com
Business Contact
 Shaker Mousa
Phone: (518) 496-2880
Email: shaker.mousa@gmail.com
Research Institution
N/A
Abstract
We plan to evaluate the chemopreventive management of solar ultraviolet (UV) mediated DNA damage by two different Nanoformulation of epigallicatechin-3-gallate (EGCG). The formulations to be assessed under this study include: a) chitosan based formulation of EGCG (nano-EGCG), and b) EGCG containing chitosan based solid lipid nanoparticles (E-Ch-SLNPs). EGCG is well-tested and popular polyphenol in skin cancer management however its efficacy has not translated to the clinic due to i) limitations of route of administration, ii) need of long-term dosing, iii) instability, and iv) inadequate bioavailability. The following Specific Aims are proposed: Aim 1: To determine if EGCG nanoformulated exhibits enhanced stability and improved release kinetics as compared to the native agent, and investigate its topical delivery capability. We will conduct ex vivo studies to study the shelf life of both nano-EGCG and further investigate its transdermal delivery. Aim 2: To determine the ex vivo and in vivo efficacy of our EGCG nanoformulations against UV mediated damages in 3D reconstituted human skin equivalent and SKH-1 hairless mouse and analyze the presence of EGCG in the mouse skin layers and blood. We will determine the comparative efficacy of nano-EGCG, ChSLNPs and EGCG under ex vivo and in vivo situations.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government